Biomarin Pharmaceutical (BMRN) - Stock & Dividends
Exchange: USA Stocks • Country: United States • Currency: USD • Type: Common Stock • ISIN: US09061G1013
BioMarin Pharmaceutical Inc. is a company that focuses on creating and selling treatments for individuals facing severe and life-threatening rare diseases and medical conditions.
They provide various commercial products including Vimizim, Naglazyme, Kuvan, Palynziq, Brineura, Voxzogo, and Aldurazyme which target conditions like mucopolysaccharidosis (MPS), phenylketonuria (PKU), ceroid lipofuscinosis, and achondroplasia.
Furthermore, BioMarin Pharmaceutical Inc. is actively involved in developing advanced treatments such as Roctavian for severe hemophilia A, BMN 331 for Hereditary Angioedema (HAE) individuals, and BMN 255 for primary hyperoxaluria as part of their commitment to improving patient care.
They cater to specialty pharmacies, hospitals, global markets, and distributors, showcasing their dedication to reaching a wide range of individuals in need of their innovative therapies.
Incorporated in 1996 in San Rafael, California, BioMarin Pharmaceutical Inc. has established license and partnership agreements with several organizations to ensure a comprehensive approach to product development and distribution.
To learn more about BioMarin Pharmaceutical Inc. and their impactful work, visit their website at https://www.biomarin.com.
Drawdown (Underwater) Chart
Overall Trend and Yearly Seasonality
BMRN Stock Overview
Market Cap in USD | 16,230m |
Sector | Healthcare |
Industry | Biotechnology |
GiC SubIndustry | Biotechnology |
TER | 0.00% |
IPO / Inception | 1999-07-23 |
BMRN Stock Ratings
Fundamental | 2.58 |
Dividend | - |
Growth 5y | 0.53 |
Rel. Performance vs Sector | -2.83 |
Analysts | 4.20/5 |
Fair Price Momentum | 73.67 USD |
Fair Price DCF | 7.50 USD |
BMRN Dividends
Yield 12m | 0.00% |
Yield on Cost 5y | 0.00% |
Dividends CAGR 5y | 0.00% |
Payout Consistency | 0.0% |
BMRN Growth Ratios
Growth 12m | -8.34% |
Growth Correlation 12m | -26% |
Growth Correlation 3m | -71% |
CAGR 5y | -0.47% |
Sharpe Ratio 12m | -0.50 |
Alpha vs SP500 12m | -31.97 |
Beta vs SP500 5y weekly | 0.70 |
ValueRay RSI | 73.43 |
Volatility GJR Garch 1y | 34.32% |
Price / SMA 50 | -0.85% |
Price / SMA 200 | -2.16% |
Current Volume | 1027.7k |
Average Volume 20d | 1219.2k |
External Links for BMRN Stock
Wall Street Journal • Benzinga • Yahoo Finance
Tweets
X (Twitter) • Stocktwits
Fund Manager Positions
Dataroma • Stockcircle
As of March 29, 2024, the stock is trading at USD 87.34 with a total of 1,027,708 shares traded.
Over the past week, the price has changed by +3.84%, over one month by -1.20%, over three months by -10.08% and over the past year by -4.48%.
According to ValueRays Forecast Model, BMRN Biomarin Pharmaceutical will be worth about 81.2 in March 2025. The stock is currently trading at 87.34. This means that the stock has a potential downside of -7.01%.
Issuer | Forecast | Upside |
---|---|---|
Wallstreet Target Price | 109.5 | 25.3% |
Analysts Target Price | 117 | 33.9% |
ValueRay Target Price | 81.2 | -7.01% |